Laryngopharyngeal Reflux
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Temple TherapeuticsNetherlands - Geleen
1 program1
Omeprazole, Lansoprazole, Esomeprazole, RantidinePhase 41 trial
Active Trials
AstraZenecaCAMBRIDGE, United Kingdom
1 programStudy of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Temple TherapeuticsOmeprazole, Lansoprazole, Esomeprazole, Rantidine
AstraZenecaStudy of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR)
Clinical Trials (2)
Total enrollment: 45 patients across 2 trials
Comparison of Voice Therapy and Antireflex Therapy in LPR
Start: May 2016Est. completion: Jan 20180
Phase 4Withdrawn
NCT00321503AstraZenecaStudy of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR)
Study of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR)
Start: May 2006Est. completion: May 200745 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.